Alnylam Pharmaceuticals
ALNY
#799
Rank
โ‚น2.960 T
Marketcap
โ‚น22,127
Share price
2.47%
Change (1 day)
-47.30%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น506.74

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น526.51. In 2025 the company made an earnings per share (EPS) of โ‚น196.13.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น506.74158.37%
2025โ‚น196.13
2023-โ‚น336.09-62%
2022-โ‚น884.5029.03%
2021-โ‚น685.51-3.36%
2020-โ‚น709.31-8.48%
2019-โ‚น775.017.67%
2018-โ‚น719.7939.74%
2017-โ‚น515.0912.94%
2016-โ‚น456.0638.84%
2015-โ‚น328.47-32.88%
2014-โ‚น489.38259.44%
2013-โ‚น136.15-31.25%
2012-โ‚น198.04

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น634.10 20.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น181.18-65.59%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น3,990 657.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น250.40-147.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น69.50-113.20%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น8.57-101.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น59.98-88.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-โ‚น317.05-160.22%๐Ÿ‡บ๐Ÿ‡ธ USA